DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose ...

Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

The healthcare industry presents a wealth of opportunities for investors to generate notable portfolio returns over decades.

Adults with type 2 diabetes who used a continuous glucose monitor and wore their sensor for more than 270 days in 1 year had ...

Abbott has initiated a medical device correction for sensors used in certain FreeStyle Libre 3 continuous glucose monitoring (CGM) systems in the US after determining that some of them may be ...

MILWAUKEE, Nov. 24, 2025 /PRNewswire/ — Ademi & Fruchter LLP is investigating possible securities fraud claims against DexCom, Inc. (NASDAQ: DXCM). The investigation results from inaccurate statements ...

The problem applies to Abbott’s Libre 3 and Libre 3 Plus sensors. The company said it has received reports of 736 severe adverse events and seven deaths.

Dexcom has announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1.

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor ...

Touchstone Sands Capital Select Growth Fund Q3 review highlights AI-driven gains and challenges. Explore insights and ...

The correction is one of the largest in Abbott's recent continuous glucose monitor business, which dominates the global ...

Abbot has issued a medical device correction for some of its glucose sensor products after identifying a manufacturing issue that can lead to falsely low glucose readings. The correction affects about ...